Pharmaceuticals

Top-Feature

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Helsinn Chemicals SA
Photo
Bayer AG
Photo
Cambrex Corporation
Thomson Reuters
Photo
WeylChem International GmbH
High Technology Associates
Chemgineering Technology GmbH
Robert Bosch GmbH
Photo
Arthur D. Little
Chemical Market Reporter
Chemtura Corp.
KPMG
Photo
Cerbios-Pharma SA
Oracle Germany
Photo
Curia
EquipNet Inc.
Clea Technologies B.V.
Photo
American Chemistry Council
Informa Markets
Dechema e.V.
Berlin Partner für Wirtschaft und Technologie GmbH
Fenton
Photo
A.T. Kearney GmbH
Photo
Oxea
Codexis
Camelot Management Consultants AG
Saltigo GmbH
Porsche Consulting
Photo
Merck KGaA
Impress PR
Dr. Partsch & Partner
Photo
AkzoNobel
Photo
Simon-Kucher & Partners Strategy & Marketing Consultants GmbH
Cedarburg Hauser Pharmaceuticals
CPA Chemical Pharmac. Ass.
Sustainability Support Services (Europe) AB
Bio Evaluation
SOCMA Society of Chemical